Azzad Asset Management Inc. ADV Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Azzad Asset Management Inc. ADV purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, HoldingsChannel reports. The fund purchased 981 shares of the biopharmaceutical company’s stock, valued at approximately $758,000.

A number of other institutional investors have also modified their holdings of the company. Resona Asset Management Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 0.3% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 32,060 shares of the biopharmaceutical company’s stock worth $24,636,000 after acquiring an additional 106 shares in the last quarter. Seelaus Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $275,000. Childress Capital Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 38.6% in the first quarter. Childress Capital Advisors LLC now owns 567 shares of the biopharmaceutical company’s stock valued at $438,000 after acquiring an additional 158 shares in the last quarter. Flatrock Wealth Partners LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth $291,000. Finally, Jackson Thornton Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 10.2% during the first quarter. Jackson Thornton Wealth Management LLC now owns 1,091 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 101 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on REGN shares. Royal Bank Of Canada decreased their price objective on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a report on Tuesday. Leerink Partners restated a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. HSBC lowered their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Canaccord Genuity Group dropped their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $787.67.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $664.52 on Friday. The company has a market cap of $70.25 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.47 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock’s fifty day moving average price is $645.30 and its 200 day moving average price is $722.39. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.22 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.33 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.